The risk for symptomatic intracranial hemorrhage was about doubled when ischemic stroke patients who undergo endovascular therapy are treated with heparin or aspirin, according to a study presented at the European Stroke Organisation Conference. The trial was halted for safety reasons, and the authors recommended avoiding the use of the studied doses for both drugs during endovascular therapy for ischemic stroke.
The pharmaceutical industry and others are turning to synthetic biology, which uses engineering and computing to reprogram cells, for a wide range of tasks. Boston's Ginkgo Bioworks was instrumental in helping Moderna with enzyme production for its COVID-19 vaccine, and the company also has assisted the agricultural industry with the production of nitrogen-fixing microbes.
The pharmaceutical industry is increasing its use of new technologies to improve manufacturing and health outcomes, such as automation of tasks and 3D printing of pills and tablets. Pharmaceutical companies are also using machine learning and artificial intelligence to analyze troves of data that could lead to the creation of personalized therapies.
Numolux Group executives say a COVID-19 vaccine manufacturing facility could be completed by the end of 2021 and could produce up to 100 million doses annually. Numolux would produce China's Sinovac vaccine, which was recently approved by South African regulators.
Kenyan health officials say a fill-and-finish facility for COVID-19 vaccines should be ready by 2022 as the country seeks to guarantee its supply. A full-scale manufacturing facility is scheduled to be completed by 2024.
Issues with data integrity cannot always be blamed on a computer problem and they are not always intentional, writes Peter Calcott, CEO of Calcott Consulting. Calcott addresses common misconceptions of data integrity issues, noting that to address and prevent these problems, "a blame-free culture that is open, where operators can raise issues without fear, must prevail."
CureVac is ending agreements with manufacturers Celonic Group of Switzerland and Germany's Wacker for the production of its COVID-19 vaccine. The German biotech firm still has deals with manufacturers Rentschler Biopharma, Bayer, Fareva and Novartis but has yet to secure regulatory approval for its vaccine.
An additional 200 million COVID-19 vaccine doses are being donated to low-income countries by the European Union, which had already pledged 250 million doses. The EU is also shoring up vaccination efforts in its member countries "to ensure that this does not turn into a pandemic of the unvaccinated," said European Commission President Ursula von der Leyen.
Mesa Laboratories has acquired Agena Bioscience in a $300 million cash deal, and the transaction is expected to be finalized by the end of the year.
Researchers from Auburn University have developed a COVID-19 test on a microchip that uses semiconductor technology and transistor biosensors to instantly reveal results after detecting the virus spike protein in a blood sample. The findings of the study, which is published in the journal ACS Nano, show a potential development for electronic biomedical sensors.